Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer

Akira Matsui; Masahiro Morise; Ichidai Tanaka; Sachiko Ozone; Reiko Matsuzawa; Junji Koyama; Tetsunari Hase; Naozumi Hashimoto; Mitsuo Sato; Yoshinori Hasegawa

doi:10.1080/07357907.2020.1793350

Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer

Akira Matsui
, Masahiro Morise
, Ichidai Tanaka
, Sachiko Ozone
, Reiko Matsuzawa
, Junji Koyama
, Tetsunari Hase
, Naozumi Hashimoto
, Mitsuo Sato
, Yoshinori Hasegawa

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10–20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.

本文言語	英語
ページ（範囲）	424-430
ページ数	7
ジャーナル	Cancer Investigation
巻	38
号	7
DOI	https://doi.org/10.1080/07357907.2020.1793350
出版ステータス	出版済み - 08-08-2020
外部発表	はい

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

腫瘍学
癌研究

文献へのアクセス

10.1080/07357907.2020.1793350

他のファイルとリンク

フィンガープリント

「Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

@article{7020e9d03f7b431bb19cb51642a06509,

title = "Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer",

abstract = "In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10{\textendash}20\% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26\%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.",

author = "Akira Matsui and Masahiro Morise and Ichidai Tanaka and Sachiko Ozone and Reiko Matsuzawa and Junji Koyama and Tetsunari Hase and Naozumi Hashimoto and Mitsuo Sato and Yoshinori Hasegawa",

note = "Publisher Copyright: {\textcopyright} 2020 Taylor \& Francis Group, LLC.",

year = "2020",

month = aug,

day = "8",

doi = "10.1080/07357907.2020.1793350",

language = "English",

volume = "38",

pages = "424--430",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "7",

}

TY - JOUR

T1 - Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer

AU - Matsui, Akira

AU - Morise, Masahiro

AU - Tanaka, Ichidai

AU - Ozone, Sachiko

AU - Matsuzawa, Reiko

AU - Koyama, Junji

AU - Hase, Tetsunari

AU - Hashimoto, Naozumi

AU - Sato, Mitsuo

AU - Hasegawa, Yoshinori

PY - 2020/8/8

Y1 - 2020/8/8

N2 - In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10–20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.

AB - In advanced non-small cell lung cancer (NSCLC), the reported incidence of febrile neutropenia (FN) caused by docetaxel (DTX) is 10–20% in clinical trial data. However, FN incidence caused by DTX in real-world setting remains unclear. We evaluated FN incidence caused by DTX and identify risk factors of FN in real-world setting. One hundred and seventy-one NSCLC patients treated with DTX were retrospectively analyzed and 44 (26%) developed FN. Multivariate analysis identified higher age (≥65 years) and prior history of FN as independent risk factors for FN. Primary prophylaxis for FN might be recommended in elderly patients with/without prior history of FN.

UR - https://www.scopus.com/pages/publications/85088876164

UR - https://www.scopus.com/pages/publications/85088876164#tab=citedBy

U2 - 10.1080/07357907.2020.1793350

DO - 10.1080/07357907.2020.1793350

M3 - Article

C2 - 32643445

AN - SCOPUS:85088876164

SN - 0735-7907

VL - 38

SP - 424

EP - 430

JO - Cancer Investigation

JF - Cancer Investigation

IS - 7

ER -